Profile of the progesterone derivative chlormadinone acetate—Pharmocodynamic properties and therapeutic applications
R Druckmann - contraception, 2009 - Elsevier
Chlormadinone acetate (CMA) is a derivative of progesterone (17α-acetoxy-6-chloro-4, 6-
pregnadiene-3, 20-dione), first synthesized in 1961 and is used as an orally effective …
pregnadiene-3, 20-dione), first synthesized in 1961 and is used as an orally effective …
Diabetes and the menopause
L Wedisinghe, M Perera - Maturitas, 2009 - Elsevier
Diabetes mellitus is the commonest chronic disease in post-menopausal women and is a
predisposing factor for cardiovascular disease, which is the leading cause of death in this …
predisposing factor for cardiovascular disease, which is the leading cause of death in this …
[HTML][HTML] Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding–ovulation dysfunction patients
L Wang, HY Guan, HX Xia, XY Chen… - World Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
BACKGROUND Dydrogesterone has shown significant efficacy in treatment of irregular
menstrual cycle due to abnormal uterine bleeding-ovulation dysfunction (AUB-O), but there …
menstrual cycle due to abnormal uterine bleeding-ovulation dysfunction (AUB-O), but there …
[HTML][HTML] Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial
G Casanova, PM Spritzer - Lipids in health and disease, 2012 - Springer
Background Much attention has been drawn to the deleterious effects of adding progestins
to estrogen as hormone therapy (HT) in postmenopausal women. Some widely prescribed …
to estrogen as hormone therapy (HT) in postmenopausal women. Some widely prescribed …
Use of dydrogesterone in hormone replacement therapy
AO Mueck, H Seeger, KJ Bühling - Maturitas, 2009 - Elsevier
According to the Women's Health Initiative (WHI) study, the most important risks during
combined hormone replacement therapy (HRT) are breast cancer, stroke and venous …
combined hormone replacement therapy (HRT) are breast cancer, stroke and venous …
[HTML][HTML] Прогестерон и беременность
МА Репина - Журнал акушерства и женских болезней, 2011 - cyberleninka.ru
Прогестерон ключевой гормон репродукции. Его агонист дидрогестерон, за
небольшими изменениями, фактически повторяет структуру прогестерона, обладает …
небольшими изменениями, фактически повторяет структуру прогестерона, обладает …
Effects of dydrogesterone on the vascular system
H Seeger, AO Mueck - Gynecological Endocrinology, 2007 - Taylor & Francis
Estrogens exert beneficial effects on the vascular system, while progestogens generally
have a negative impact (eg vasoconstrictor effects on the arterial system). In contrast …
have a negative impact (eg vasoconstrictor effects on the arterial system). In contrast …
Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow
CE Fernandes, LM Pompei, RB Machado, JAS Ferreira… - Maturitas, 2008 - Elsevier
OBJECTIVES: To evaluate the lipid profile, insulin resistance and vasomotricity, and the
interaction between these factors, in postmenopausal women receiving hormone therapy …
interaction between these factors, in postmenopausal women receiving hormone therapy …
Melatonin supplementation therapy as a potent alternative to ERT in ovariectomized rats
Aim To evaluate the efficacy of melatonin supplementation therapy as an alternative to
estrogen replacement therapy in an ovariectomized rat model and to assess diabetogenic …
estrogen replacement therapy in an ovariectomized rat model and to assess diabetogenic …
[PDF][PDF] Дидрогестерон-прогестаген успешной беременности
МА Репина - Гинекология, 2011 - omnidoctor.ru
Резюме Представлен обзор данных литературы, посвященных исследованию
дидрогестерона как прогестагена, обеспечивающего успешную поддержку …
дидрогестерона как прогестагена, обеспечивающего успешную поддержку …